Organ-specific proteins and methods of their use

1. A method for detecting an abnormal prostate state in a subject comprising,

a) contacting a blood sample from the subject with a panel of at least four detection reagents wherein each detection reagent is specific for one prostate-specific protein; wherein the prostate-specific proteins are selected from the prostate-specific protein set as follows;

SEQ

Gene

Protein ID

ID NO

Description

ANXA8*&

NP_001621

384

annexin A8

CAV1&

NP_001744

1351

caveolin 1

CLCA2*

NP_006527

59346

calcium activated chloride

channel 2

COL17A1*

NP_000485

59347

alpha 1 type XVII collagen

H2BFS

NP_059141

65564

H2B histone family, member S

HIST1H2BC

NP_003517

65565

H2B histone family, member L

HIST1H2BD&

NP_066407

14604

H2B histone family, member B

HIST1H2BE

NP_003514

65566

H2B histone family, member H

HIST1H2BJ

NP_066402

65567

H2B histone family, member R

HIST1H2BM

NP_003512

65568

H2B histone family, member E

HIST1H2BN

NP_003511

65569

H2B histone family, member D

HIST1H2BO

NP_003518

65570

histone H2B

HNT*&

NP_057606

4329

neurotrimin

IL1A*

NP_000566

59357

interleukin 1, alpha proprotein

KRT6A*&

NP_005545

6225

keratin 6A

KRT6B*&

NP_005546

17263

keratin 6B

KRT6C*&

NP_490596

6226

keratin 6C

LAMA3*

NP_000218

59362

laminin alpha 3 subunit

isoform 2

LAMA3*

NP_937762

59363

laminin alpha 3 subunit

isoform 1

LAMB3*

NP_000219

59364

laminin subunit beta 3 precursor

LAMB3*

NP_001017402

59365

laminin subunit beta 3 precursor

LOC653107*

XP_931601

65577

PREDICTED: similar to

Annexin A8 (Annexin VIII)

(Vascular anticoagulant-beta)

(VAC-beta) isoform 1

LOC653107*

XP_936422

65578

PREDICTED: similar to

Annexin A8 (Annexin VIII)

(Vascular anticoagulant-beta)

(VAC-beta) isoform 2

LOC653107*

XP_936471

65585

PREDICTED: similar to

Annexin A8 (Annexin VIII)

(Vascular anticoagulant-beta)

(VAC-beta) isoform 10

LOC653107*

XP_936481

65587

PREDICTED: similar to

Annexin A8 (Annexin VIII)

(Vascular anticoagulant-beta)

(VAC-beta) isoform 12

LOC653107*

XP_936484

65588

PREDICTED: similar to

Annexin A8 (Annexin VIII)

(Vascular anticoagulant-beta)

(VAC-beta) isoform 13

LOC653107*

XP_936492

65589

PREDICTED: similar to

Annexin A8 (Annexin VIII)

(Vascular anticoagulant-beta)

(VAC-beta) isoform 14

MASP1*&

NP_624302

14670

mannan-binding lectin serine

protease 1 isoform 2 precursor

S100A2&

NP_005969

30938

S100 calcium binding

protein A2

SCRN3*

NP_078859

65605

secernin 3

SEMA3C*

NP_006370

65606

semaphorin 3C

SEPT11*&

NP_060713

4577

septin 11

SERPINB5*

NP_002630

59403

serine (or cysteine) proteinase

inhibitor, clade B (ovalbumin),

member 5

SFN*

NP_006133

59405

stratifin

b) measuring the amount of prostate-specific protein detected in the blood sample by each detection reagent; and

c) comparing the amount of prostate-specific protein detected in the blood sample by each detection reagent to a predetermined normal control amount for each respective prostate-specific protein;

wherein a statistically significant altered level in said prostate-specific proteins indicates a perturbation in the normal biological state.

2. The method of claim 1 wherein the amounts of at least five prostate-specific proteins are measured and compared to normal control amounts.

3. The method of claim 1 wherein the amounts of at least ten prostate-specific proteins are measured and compared to normal control amounts.

4. A panel of reagents for use in a method to detect abnormal prostate state in a subject comprising at least four detection reagents wherein each detection reagent is specific for one prostate-specific protein; wherein the prostate-specific proteins are selected from the prostate-specific protein set of claim 1 .

5. The panel of claim 4 comprising at least five prostate-specific protein reagents.

6. The panel of claim 4 comprising at least ten prostate-specific protein reagents.